Tonix Pharmaceuticals (TNXP) Downgraded by ValuEngine

ValuEngine downgraded shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a sell rating to a strong sell rating in a research note released on Sunday morning.

Separately, Aegis reissued a buy rating on shares of Tonix Pharmaceuticals in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $8.33.

Shares of Tonix Pharmaceuticals (TNXP) traded down $0.09 during mid-day trading on Friday, reaching $3.61. 46,200 shares of the company’s stock traded hands, compared to its average volume of 57,450. The firm has a market cap of $28.16, a price-to-earnings ratio of -1.07 and a beta of 2.62. Tonix Pharmaceuticals has a 52 week low of $2.85 and a 52 week high of $9.40.

In other Tonix Pharmaceuticals news, Director Ernest Mario sold 10,000 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $3.57, for a total transaction of $35,700.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $35,700. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 48,934 shares of company stock valued at $172,496. 4.00% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. B. Riley Financial Inc. purchased a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 378,138 shares of the company’s stock, valued at approximately $1,637,000. B. Riley Financial Inc. owned about 5.05% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3125781/tonix-pharmaceuticals-tnxp-downgraded-by-valuengine.html.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company?s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.